According to a recent LinkedIn post from Glooko, the company is present at the 2026 Society of Hospital Medicine Converge Conference to showcase its EndoTool Glucose Management System. The technology, developed by Monarch Medical Technologies, which Glooko identifies as a Glooko company, is presented as a tool for redefining inpatient insulin management.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that EndoTool is being positioned as a solution to support hospitals with mandatory CMS glycemic safety reporting, with visitors directed to booth 503 for more information. For investors, this emphasis on hospital-focused insulin management and regulatory reporting suggests Glooko is targeting mission-critical clinical workflows, which could support recurring enterprise revenue and deepen integration within hospital systems.
By aligning its offering with mandatory CMS reporting requirements, the post implies that Glooko is seeking to benefit from regulatory drivers that may increase demand for glycemic safety solutions. If the company can demonstrate clear clinical and operational value at scale, this strategy could strengthen its competitive position in the hospital diabetes management segment and enhance its long-term growth prospects.